<DOC>
	<DOC>NCT02557139</DOC>
	<brief_summary>Bioavailability, Phase I study to evaluate the clinical performance of the tablet formulation in the fasted and fed states, in comparison to the capsule formulation in the fed state.</brief_summary>
	<brief_title>Bioavailability of KD025 in Healthy Male Subjects Completed in the UK</brief_title>
	<detailed_description>A 200 mg tablet formulation of KD025 is being developed at Quotient Clinical to replace the capsule formulation. This Phase I study will evaluate the clinical performance of the tablet formulation in the fasted and fed states, in comparison to the capsule formulation in the fed state.</detailed_description>
	<criteria>Body mass index 18.0 to 30.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator Good state of health (mentally and physically) as indicated by a comprehensive clinical assessment (detailed medical history and a complete physical examination), ECG and laboratory investigations (hematology, coagulation, clinical chemistry and urinalysis) Must be willing and able to communicate and participate in the whole study Must provide written informed consent Must agree to use an adequate method of contraception for up to 90 days post discharge Participation in a clinical research study within the previous 3 months Subjects who are study site employees, or immediate family members of a study site or sponsor employee Subjects who have previously been enrolled in this study History of any drug or alcohol abuse in the past 2 years Regular alcohol consumption &gt;21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine) Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening Clinically significant abnormal biochemistry, haematology, coagulation or urinalysis as judged by the investigator Positive drugs of abuse test result or alcohol breath test Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results History of any clinically significant cardiovascular, renal, hepatic, chronic respiratory or GI disease that may compromise the subject safety or interfere with the objectives of the study as judged by the investigator Subject has a history or presence of any of the following: 1. Active GI disease requiring therapy 2. Hepatic disease and/or ALT or AST &gt;1.5 × ULN at screening 3. Renal disease and/or serum creatinine &gt;1.5 × ULN at screening 4. Other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs Subject has QT interval corrected using Fridericia's formula (QTcF) intervals &gt;450 msec at the screening or admission ECG Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients Subject has a known sensitivity to ROCK2 inhibitor agents or to any of the constituents of the KD025 formulation Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active Donation or loss of greater than 400 mL of blood within the previous 3 months Subjects who are taking, or have taken, any prescribed or overthecounter drug (other than 4 g per day paracetamol) or herbal remedies in the 14 days before IMP administration Failure to satisfy the investigator of fitness to participate for any other reason</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>